The upward drift in VTRS stock price has coincided with analyst rating upgrades from “Hold” to “Buy.” Fundamentals such as ROE improvement and debt refinancing are cited as catalysts. However, as of September 3, drug developers had raised $2 billion through initial public offerings (IPOs) this year, a 24% increase over the same period in 2023. However, according to BNN Bloomberg, over two-thirds of these funds were raised in the first two months as a result of a spike in new listings. However, pharma companies' portion of U.S. IPO profits has decreased from 17% in February to 6.5%, with less than $800 million raised in the next six months. S&P Global also highlighted this trend in a recent report, noting that global dividend growth saw a sharp rise in 2024, climbing by an impressive 8.5%. The surge was especially strong in Asia-Pacific, where government policies encouraged companies to shift from annual to semiannual dividend distributions. At the same time, the US market experienced a wave of new and reinstated dividend payments, largely fueled by companies in the technology, media, and telecommunications (TMT) sectors. VTRS stock price jumped 2.2% intraday following news of expanded commercial agreements in Europe. Market watchers expect this to enhance top-line growth, offsetting declines in mature product segments.
